Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Urology. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Urology

Journal Scan / Research · October 05, 2022

Outcomes of BCG Treatment in Patients With Carcinoma In Situ of the Bladder With or Without Associated Ta/T1 Disease

European Urology Focus


Additional Info

European Urology Focus
Long-term Recurrence and Progression Patterns in a Contemporary Series of Patients with Carcinoma In Situ of the Bladder With or Without Associated Ta/T1 Disease Treated with Bacillus Calmette-Guérin: Implications for Risk-adapted Follow-up
Eur Urol Focus 2022 Sep 23;[EPub Ahead of Print], JD Subiela, Ó Rodríguez Faba, J Aumatell, DA Gonzalez-Padilla, A Rosales Bordes, J Huguet, W Krajewski, F Algaba, D López Curtis, J Brasero Burgos, Á Sánchez González, MÁ Jiménez Cidre, FJ Burgos Revilla, A Breda, J Palou

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading